NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$122.34 -0.79 (-0.64 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$123.13
Today's Range$122.20 - $125.68
52-Week Range$36.58 - $127.77
Volume242,300 shs
Average Volume223,546 shs
Market Capitalization$2.42 billion
P/E Ratio135.05
Dividend YieldN/A
Beta1.01
Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Debt-to-Equity RatioN/A
Current Ratio17.86
Quick Ratio17.86

Price-To-Earnings

Trailing P/E Ratio135.05
Forward P/E Ratio36.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales22.93
Cash Flow$1.0480 per share
Price / Cash116.74
Book Value$15.80 per share
Price / Book7.74

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins31.60%
Return on Equity18.50%
Return on Assets17.30%

Miscellaneous

Employees89
Outstanding Shares19,270,000
Market Cap$2,420.01

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.08. The biotechnology company had revenue of $44 million for the quarter, compared to analyst estimates of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. Enanta Pharmaceuticals's quarterly revenue was up 388.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.28) earnings per share. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

5 Wall Street analysts have issued twelve-month target prices for Enanta Pharmaceuticals' shares. Their forecasts range from $36.00 to $135.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $79.1667 in the next year. This suggests that the stock has a possible downside of 35.3%. View Analyst Ratings for Enanta Pharmaceuticals.

What is the consensus analysts' recommendation for Enanta Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
  • Mr. Paul J. Mellett Jr., Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer (Age 63)
  • Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Press coverage about ENTA stock has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.87 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.10%), James Investment Research Inc. (0.10%), Fisher Asset Management LLC (0.08%), Municipal Employees Retirement System of Michigan (0.02%), Hartford Investment Management Co. (0.02%) and Amalgamated Bank (0.01%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Which institutional investors are selling Enanta Pharmaceuticals stock?

ENTA stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was purchased by a variety of institutional investors in the last quarter, including James Investment Research Inc., Hartford Investment Management Co., Amalgamated Bank and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $122.34.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $2.42 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  199 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.